Asia’s healthcare digitization story reads well in press releases. National digital health missions, AI diagnostic pilots, and telehealth platform launches have become a fixture of health ministry announcements from New Delhi to Jakarta to Seoul. But a closer look at where capital and infrastructure are actually landing tells a more uneven story. For investors, hospital operators, and policymakers trying to allocate resources sensibly, the gap between what gets announced and what gets deployed at scale is more than a communications issue. It is a decision-relevant signal.
The announcement layer
The headlines are genuinely impressive. Venture capital backed this narrative with roughly US$12.8 billion across almost 2,000 deals in Asian health-tech startups in a single recent year, concentrated in AI diagnostics, telehealth platforms, and remote monitoring.
Governments have matched the enthusiasm. Digital health across the region is moving out of its experimentation phase, with rapid pilots giving way to scaled deployments and tighter governance. In Australia, health technology leaders describe 2026 as a period when AI moves from pilots to mainstream use, powering predictive analytics and clinical decision support. China’s medical device regulator, meanwhile, had cleared 154 AI-based medical devices by 2025, the large majority in the highest-risk classification and concentrated in radiology and imaging. On paper, this looks like a region moving decisively from pilot to scale.
What the deployment data actually shows
Market-sizing data tells a more selective story about where that momentum has actually converted into durable infrastructure. Diagnostics and laboratory capacity, arguably the least glamorous corner of healthcare digitization, is where the real money has settled.
China’s clinical laboratory services market is valued at more than US$26 billion, a base large enough to be described as institutionally well anchored rather than experimental. India’s equivalent market is smaller, at US$9 billion, but growing at more than 8 percent annually, a materially faster clip than China’s, suggesting India is still in the capacity-building phase rather than the optimization phase. Southeast Asia’s clinical laboratory services market sits at US$5 billion, while Vietnam’s diagnostic labs segment alone is projected to grow from US$1.23 billion to more than US$2 billion by 2032.
This is a meaningful distinction. Diagnostic and laboratory infrastructure is physical, capital-intensive, and slow to build. It does not generate the same press coverage as a telehealth app launch or an AI triage pilot, but it is a far more reliable indicator of where health systems are actually investing for the long term. The fact that this is where sustained growth is concentrated suggests that the more visible digitization narrative, built around software platforms and AI pilots, may be running ahead of the underlying infrastructure that makes those tools clinically useful in the first place.
Where the gap is real and where it is closing
The picture is not uniformly cautionary. Some markets have genuinely closed the gap between announcement and deployment. South Korea’s near-universal, heavily digitized national health insurance system has given its AI diagnostics and medical imaging companies a real operational base rather than just a pilot environment. China’s approval pipeline for AI medical devices, weighted toward high-risk clinical categories, indicates that regulatory infrastructure is catching up with the technology rather than lagging behind it.
Southeast Asia presents a different but equally instructive pattern. Telehealth adoption there has been driven less by hospital digitization strategy and more by structural necessity, with rural physician shortages as severe as one per 10,000 people pushing mobile-first health apps into a genuine access role rather than a convenience layer. Regional super-apps folding teleconsultation into existing consumer ecosystems have made this adoption durable rather than pandemic-driven, creating a meaningfully different growth pattern from a government-announced pilot program.
The gap remains widest in the middle tier: markets with active digital health announcements and venture funding but without Korea’s insurance infrastructure, China’s regulatory throughput, or Southeast Asia’s structural access pressure forcing genuine adoption. In these markets, digital projects more often fail because of poor clinician workflow integration and procurement mismatch than because of shortcomings in the underlying technology, a solvable but frequently under-addressed problem.
What this means for decision-makers
For investors, the practical takeaway is that market-entry timing should be informed by infrastructure maturity signals, such as sustained diagnostic and laboratory capacity growth, rather than by the volume of government digitization announcements in a given market.
For hospital operators evaluating vendor partnerships, clinician workflow integration and procurement alignment deserve at least as much diligence as the underlying AI model’s accuracy claims.
For policymakers, the lesson from Korea and China is that regulatory throughput and payment infrastructure are not downstream administrative details. The World Economic Forum has framed this directly: the technology already exists, and the real challenge is adoption at scale, done in a way that strengthens equity rather than widening gaps.
Asia’s healthcare digitization is real, but it is not evenly distributed, and it is not always where the announcements suggest it is. The markets making the fastest genuine progress are those where digital tools are solving a structural problem, whether that is Korea’s insurance-backed clinical AI, China’s regulatory-cleared diagnostic devices, or Southeast Asia’s access-driven telehealth adoption. For everyone else, the underlying capacity data, rather than the press release calendar, remains the more reliable guide.
Amit Yadav is the CEO and Co-Founder of Vyansa Intelligence, a global B2B market research and business intelligence company. He brings more than 15 years of business consulting and management experience, with deep expertise in market research methodology, competitive intelligence, and strategic advisory across mobility, infrastructure, and technology sectors.
TNGlobal INSIDER publishes contributions relevant to entrepreneurship and innovation. You may submit your own original or published contributions subject to editorial discretion.
Featured image: National Cancer Institute on Unsplash
India’s AI future depends on an infrastructure challenge few are talking about